Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICRO-K vs KAON CL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the principal intracellular cation, essential for maintaining cellular tonicity, electrical neutrality, and enzymatic reactions. It modulates neuromuscular transmission, cardiac contractility, and acid-base balance.
Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.
Treatment of hypokalemia,Prevention of hypokalemia in patients at risk (e.g., on diuretics, digitalis)
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving digitalis and diuretics,Off-label: prevention of hypokalemia in patients on potassium-wasting diuretics
Oral: 20-40 m Eq (1-2 capsules) two to four times daily; maximum 100 m Eq/day. Each capsule contains 8 m Eq (600 mg) of potassium chloride in a wax matrix extended-release formulation.
Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).
Not applicable; potassium is an electrolyte with no true elimination half-life; whole-body turnover half-life is approximately 12-24 hours, clinically relevant for dosing intervals.
Terminal half-life is approximately 0.5–1.5 hours in healthy individuals; prolonged in renal impairment (up to 6–12 hours in end-stage renal disease).
Potassium ions are not metabolized; they are primarily excreted unchanged by the kidneys (90%), with minor losses via feces and sweat.
Not significantly metabolized; primarily excreted unchanged by the kidneys, with minor fecal elimination.
Renal: approximately 90% of absorbed potassium is excreted in urine; biliary/fecal: less than 10% eliminated via feces.
Primarily renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
None; potassium is not significantly bound to plasma proteins.
Minimal protein binding (<1%); not significantly bound to plasma proteins.
0.5-0.7 L/kg; total body water distribution; clinically indicates extensive intracellular uptake (98% intracellular).
Approximately 0.5–0.8 L/kg; distributes mainly in extracellular fluid, with minimal intracellular penetration.
Oral: approximately 80-90% for Micro-K (extended-release); absorption occurs in small intestine.
Oral bioavailability is ~90-100% due to complete absorption of potassium chloride; food may slightly reduce absorption but overall high.
e GFR ≥60 m L/min: No adjustment. e GFR 30-59: Reduce dose by 25-50% and monitor potassium. e GFR 15-29: Reduce dose by 50-75% and monitor potassium. e GFR <15: Avoid use or use with extreme caution; maximum 20 m Eq/day with frequent monitoring.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: use with caution, reduce dose and monitor serum potassium; GFR < 10 m L/min: contraindicated due to risk of hyperkalemia.
No specific dosing adjustments recommended for hepatic impairment. Monitor potassium levels as hepatic disease may affect potassium homeostasis.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of hyperkalemia from potential electrolyte disturbances.
Oral: <1 year: 1-2 m Eq/kg/day divided 2-4 times. 1-18 years: 1-3 m Eq/kg/day divided 2-4 times; maximum 100 m Eq/day. Extended-release capsules not recommended for children unable to swallow whole capsules.
Dose determined by physician based on serum potassium levels and underlying condition; typical oral dose: 1-3 m Eq/kg/day in divided doses, not to exceed 1 m Eq/kg per single dose or maximum 4 m Eq/kg/day. Extended-release tablets not recommended for children < 12 years unless specifically directed.
Start at low end of dosing range (20-40 m Eq/day) due to decreased renal function; maximum 100 m Eq/day. Monitor renal function and potassium levels closely.
Elderly patients often have reduced renal function and may require lower starting doses (e.g., 20 m Eq twice daily) with close monitoring of serum potassium and renal function. Avoid if e GFR < 30 m L/min/1.73 m².
None
Potassium chloride can cause hyperkalemia and cardiac arrest if administered too rapidly or in excessive doses. Avoid use in patients with severe renal impairment or conditions that predispose to hyperkalemia.
Hyperkalemia risk, especially in patients with renal impairment, diabetes, or those receiving potassium-sparing diuretics, ACE inhibitors, or ARBs,Suspect gastrointestinal obstruction or perforation with slow-release formulations; caution in patients with severe GI disorders,Use with caution in patients with cardiac disease, particularly those on digoxin,Monitor serum potassium levels regularly
Hyperkalemia risk, especially in renal impairment,Avoid solid oral forms in patients with esophageal stricture or delayed GI transit,May exacerbate metabolic alkalosis,Monitor serum potassium levels regularly
Hyperkalemia (serum potassium >5.5 m Eq/L),Renal failure or severe renal impairment (e.g., oliguria, anuria),Addison's disease,Acute dehydration,Concomitant use with potassium-sparing diuretics (e.g., amiloride, spironolactone, triamterene),Concomitant use with eplerenone,Solid dosage forms in patients with delayed gastric emptying or esophageal compression
Hyperkalemia,Severe renal impairment (oliguria, anuria, or azotemia),Concurrent use of potassium-sparing diuretics or ACE inhibitors (with caution),Untreated Addison's disease,Acute dehydration or heat cramps
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes, tomatoes) and potassium-based salt substitutes. Consuming large amounts of these may increase risk of hyperkalemia.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium, as they may increase risk of hyperkalemia. Taking with food reduces gastrointestinal irritation.
Potassium chloride (Micro-K) is not associated with major congenital malformations. Normal maternal serum potassium levels are required for fetal development. Hypokalemia or hyperkalemia may increase risks. No trimester-specific risks documented.
Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.
Potassium is a normal constituent of breast milk. Supplemental potassium does not affect milk potassium content. M/P ratio not applicable. Use with caution if maternal renal function impaired.
Potassium is a normal component of breast milk. Exogenous potassium does not significantly alter milk levels. M/P ratio not established; considered compatible with breastfeeding.
No standard dose reduction required. Pharmacokinetic changes in pregnancy (increased GFR, blood volume) may increase potassium requirements or decrease serum levels; monitor and adjust dose to maintain normal serum potassium (3.5-5.0 m Eq/L).
No dose adjustment required for potassium chloride in pregnancy; pharmacokinetics are substantially unchanged.
Micro-K (potassium chloride extended-release) is used to prevent and treat hypokalemia. Avoid use in severe renal impairment, metabolic acidosis, or conditions with high potassium levels. Slow-release formulations reduce GI irritation but may be contraindicated in patients with GI motility disorders. Do not crush or chew capsules; administer with food and a full glass of water. Monitor serum potassium and renal function regularly.
KAON CL is a potassium chloride supplement. Monitor serum potassium levels frequently, especially in patients with renal impairment or those on ACE inhibitors/ARBs, NSAIDs, or potassium-sparing diuretics to avoid hyperkalemia. Administer with food to minimize gastrointestinal irritation. Do not crush or chew extended-release formulations; swallow whole. Hypomagnesemia can cause refractory hypokalemia; check magnesium levels if potassium repletion fails.
Take this medication with food and a full glass of water to reduce stomach upset.,Swallow the capsule whole; do not crush, chew, or open it.,Do not suddenly stop taking this medication without consulting your doctor.,Avoid salt substitutes or potassium-containing supplements unless approved by your doctor.,Seek immediate medical attention if you experience signs of high potassium levels: muscle weakness, irregular heartbeat, or tingling in hands/feet.
Take this medication with a full glass of water and with food to reduce stomach upset.,Do not crush, chew, or break extended-release tablets; swallow them whole.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms of high potassium such as muscle weakness, irregular heartbeat, numbness/tingling, or confusion.,Keep all appointments for blood tests to monitor kidney function and potassium levels.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICRO-K vs KAON CL, answered by our medical review team.
MICRO-K is a Electrolyte Supplement (Potassium) that works by Potassium is the principal intracellular cation, essential for maintaining cellular tonicity, electrical neutrality, and enzymatic reactions. It modulates neuromuscular transmission, cardiac contractility, and acid-base balance.. KAON CL is a Electrolyte Supplement (Potassium) that works by Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICRO-K and KAON CL depend on the specific clinical indication. These are both Electrolyte Supplement (Potassium) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICRO-K is: Oral: 20-40 m Eq (1-2 capsules) two to four times daily; maximum 100 m Eq/day. Each capsule contains 8 m Eq (600 mg) of potassium chloride in a wax matrix extended-release formulation.. The standard adult dose of KAON CL is: Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICRO-K and KAON CL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICRO-K is classified as Category C. Potassium chloride (Micro-K) is not associated with major congenital malformations. Normal maternal serum potassium levels are required for fetal development. Hypokalemia or hyperk. KAON CL is classified as Category C. Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.